Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer
Completed · Phase 1
Conditions studied: Breast Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy in different ways, such as into the breast ducts, may kill more tumor cells. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase I trial is studying the side effects and best dose of liposomal doxorubicin when given before mastectomy in treating women with invasive breast cancer.
Key facts
- Study ID
- NCT00290732
- Run by
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- People needed
- 20
- Starts
- 2005-11-01
- Expected to finish
- 2011-10-01
- Last updated by the study team
- 2013-10-31
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Indiana University Melvin and Bren Simon Cancer Center — Indianapolis, Indiana, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.